Anti-VEGFA antibody [VG-1] (ab1316)
- Datasheet
- References (110)
- Protocols
Overview
-
Product nameAnti-VEGFA antibody [VG-1]
See all VEGFA primary antibodies -
DescriptionMouse monoclonal [VG-1] to VEGFA
-
Host speciesMouse
-
SpecificityDetects the 121, 165 and 189 VEGF isoforms in routinely fixed specimens.
-
Tested applicationsSuitable for: ICC/IF, IP, WB, ELISA, ICC, IHC-P, IHC-Frmore details
-
Species reactivityReacts with: Mouse, Rat, Rabbit, Dog, Human
Does not react with: Cow -
Immunogen
BALB/C mice were injected with a recombinant VEGF protein.
-
Positive control
- Purchase matching WB positive control:Recombinant Human VEGFA protein
- Corpus luteum, VEGF165 recombinant protein, astrocytoma or hemoangiosarcoma IHC/P: Human cerebellum, Rat cerebellum
-
General notes
Western blot protocol advice:
Please note that expression of VEGFA is low in most samples without treatment (e.g. hypoxia / DFX / CoCl2). Cell treatment with a Golgi inhibitor (e.g. brefeldin A) may enhance detection. Loading a high amount of sample (>50 µg) and addition of protease inhibitors (e.g. ab65621) may also enhance detection.This antibody clone is manufactured by Abcam. If you require a custom buffer formulation or conjugation for your experiments, please contact orders@abcam.com.
Abcam recommended secondaries - Goat Anti-Mouse HRP (ab205719) and Goat Anti-Mouse Alexa Fluor® 488 (ab150113).
Properties
-
FormLiquid
-
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle.
-
Storage bufferpH: 7.40
Preservative: 0.02% Sodium azide
Constituent: PBS
Some batches contain 6.97% L-Arginine as a stabilizing agent. For lot-specific buffer information, please contact our Scientific Support team. -
Concentration information loading... -
PurityProtein G purified
-
ClonalityMonoclonal
-
Clone numberVG-1
-
IsotypeIgG1
-
Light chain typekappa
-
Research areas
Associated products
-
Alternative Versions
-
Compatible Secondaries
-
Immunohistochemistry kits
-
Isotype control
-
Recombinant Protein
-
Related Products
Applications
Our Abpromise guarantee covers the use of ab1316 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
| Application | Abreviews | Notes |
|---|---|---|
| ICC/IF | Use a concentration of 5 µg/ml. | |
| IP | 1/1000. See Abreview. |
|
| WB | Use a concentration of 5 - 10 µg/ml. Please note in our hands this antibody is sensitive to blocking conditions. If you are seeing no bands on your western blot, we suggest using 3% milk for 1 hr at RT for blocking. For the primary antibody incubation step, we suggest 1 hr at RT rather than overnight at 4°C. We would also recommend incubating primary and secondary antibodies in TBST only. |
|
| ELISA | Use at an assay dependent concentration. | |
| ICC | Use a concentration of 10 µg/ml. See Abreview. | |
| IHC-P | Use a concentration of 5 µg/ml. Perform heat mediated antigen retrieval before commencing with IHC staining protocol. | |
| IHC-Fr | Use at an assay dependent concentration. |
Target
-
FunctionGrowth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. NRP1/Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. Isoform VEGF165B binds to KDR but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth.
-
Tissue specificityIsoform VEGF189, isoform VEGF165 and isoform VEGF121 are widely expressed. Isoform VEGF206 and isoform VEGF145 are not widely expressed.
-
Involvement in diseaseDefects in VEGFA are a cause of susceptibility to microvascular complications of diabetes type 1 (MVCD1) [MIM:603933]. These are pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis.
-
Sequence similaritiesBelongs to the PDGF/VEGF growth factor family.
-
Cellular localizationSecreted. VEGF121 is acidic and freely secreted. VEGF165 is more basic, has heparin-binding properties and, although a signicant proportion remains cell-associated, most is freely secreted. VEGF189 is very basic, it is cell-associated after secretion and is bound avidly by heparin and the extracellular matrix, although it may be released as a soluble form by heparin, heparinase or plasmin.
- Information by UniProt
-
Database links
- Entrez Gene: 7422 Human
- Entrez Gene: 22339 Mouse
- Entrez Gene: 100008899 Rabbit
- Entrez Gene: 83785 Rat
- Omim: 192240 Human
- SwissProt: P15692 Human
- SwissProt: Q00731 Mouse
- SwissProt: P16612 Rat
see all -
Alternative names
- Folliculostellate cell-derived growth factor antibody
- Glioma-derived endothelial cell mitogen antibody
- MGC70609 antibody
see all
Images
-
![Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-VEGFA antibody [VG-1] (ab1316)](https://www.abcam.com/ps/products/1/ab1316/Images/ab1316-249579-IHCGR1952981015ugNaC.jpg)
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-VEGFA antibody [VG-1] (ab1316)IHC image of ab1316 staining VEGF in human cerebellum formalin fixed paraffin embedded tissue sections, performed on a Leica Bond. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH6, epitope retrieval solution 1) for 20 mins. The section was then incubated with ab1316, 5μg/ml working concentration, for 15 mins at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX. No primary antibody was used in the secondary only control (shown on the inset).
For other IHC staining systems (automated and non-automated) customers should optimize variable parameters such as antigen retrieval conditions, primary antibody concentration and antibody incubation times. -
![Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-VEGFA antibody [VG-1] (ab1316)](https://www.abcam.com/ps/products/1/ab1316/Images/ab1316-249580-IHCGR1952981015ugNaC.jpg)
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-VEGFA antibody [VG-1] (ab1316)IHC image of ab1316 staining VEGF in rat cerebellum formalin fixed paraffin embedded tissue sections, performed on a Leica Bond. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH6, epitope retrieval solution 1) for 20 mins. The section was then incubated with ab1316, 5μg/ml working concentration, for 15 mins at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX. No primary antibody was used in the secondary only control (shown on the inset).
For other IHC staining systems (automated and non-automated) customers should optimize variable parameters such as antigen retrieval conditions, primary antibody concentration and antibody incubation times. -
![Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-VEGFA antibody [VG-1] (ab1316)](https://www.abcam.com/ps/products/1/ab1316/Images/VEGF-Primary-antibodies-ab1316-11.jpg)
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-VEGFA antibody [VG-1] (ab1316)This image is courtesy of an anonymous Abreviewab1316 staining VEGF in Human MDA-MD-231 cells injected into the mouse mammary fat pad by Immunohistochemistry (IHC-P - formaldehyde-fixed, paraffin-embedded sections). Tissue was fixed with paraformaldehyde, permeabilized with Tween in PBS and blocked with 1.5% serum for 1 hour at 25°C; antigen retrieval was by heat mediation in citrate buffer. Tissue samples were incubated with primary antibody (1/200 in PBST +1% BSA) for 16 hours at 4°C. A biotin-conjugated Goat anti-mouse IgG polyclonal (1/200) was used as the secondary antibody. Tissue was counterstained with Hematoxylin (1/10) for 30 seconds at room temperature and rinsed with water. -
![Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-VEGFA antibody [VG-1] (ab1316)](https://www.abcam.com/ps/products/1/ab1316/Images/VEGF-Primary-antibodies-ab1316-45.jpg)
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-VEGFA antibody [VG-1] (ab1316)IHC image of ab1316 staining in human heart formalin fixed paraffin embedded tissue section, performed on a Leica BondTM system using the standard protocol F. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH6, epitope retrieval solution 1) for 20 mins. The section was then incubated with ab1316, 5µg/ml, for 15 mins at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.
For other IHC staining systems (automated and non-automated) customers should optimize variable parameters such as antigen retrieval conditions, primary antibody concentration and antibody incubation times. -
![Immunocytochemistry/ Immunofluorescence - Anti-VEGFA antibody [VG-1] (ab1316)](https://www.abcam.com/ps/products/1/ab1316/Images/ab1316_1 copy.jpg)
Immunocytochemistry/ Immunofluorescence - Anti-VEGFA antibody [VG-1] (ab1316)ab1316 at 10µg/ml staining human retinal pigment epithelial cells. The antibody was incubated with the cells for 6 hours and then detected with Alexa-Fluor ® 568 goat anti-mouse (IgG) antibody.
This image is courtesy of an Abreview submitted on 16 November 2005.
-
![Immunocytochemistry/ Immunofluorescence - Anti-VEGFA antibody [VG-1] (ab1316)](https://www.abcam.com/ps/products/1/ab1316/Images/VEGF-Primary-antibodies-ab1316-3.jpg)
Immunocytochemistry/ Immunofluorescence - Anti-VEGFA antibody [VG-1] (ab1316)ICC/IF image of ab1316 stained HeLa cells. The cells were 100% methanol fixed (5 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab1316, 10µg/ml) overnight at +4°C. The secondary antibody (green) was Alexa Fluor® 488 goat anti-mouse IgG (H+L) used at a 1/1000 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM. This antibody also gave a positive result in 100% methanol fixed (5 min) Hek293, HepG2 and MCF7 cells at 10µg/ml, and in 4% PFA fixed (10 min) HeLa, Hek293, HepG2 and MCF7 cells at 10µg/ml. -
![Western blot - Anti-VEGFA antibody [VG-1] (ab1316)](https://www.abcam.com/ps/products/1/ab1316/Images/ab1316-291204-ID1204Ab1316GR145343110secDS.jpg)
Western blot - Anti-VEGFA antibody [VG-1] (ab1316)All lanes : Anti-VEGFA antibody [VG-1] (ab1316)
Lane 1 :Recombinant Human VEGFA protein (ab204773)
Lane 2 :Recombinant mouse VEGFA protein (Active) (ab185265)
Lysates/proteins at 0.1 µg per lane.
Secondary
All lanes : Mouse IgG secondary antibody at 1/10000 dilution
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 24, 45 kDa
Observed band size: 23 kDa why is the actual band size different from the predicted?
Exposure time: 10 secondsThis blot was produced using a 10% Bis-tris gel under the MES buffer system. The gel was run at 200V for 35 minutes before being transferred onto a Nitrocellulose membrane at 30V for 70 minutes. The membrane was then blocked for an hour using 3% Milk before being incubated with ab1316 overnight at 4°C. Antibody binding was detected using an anti-mouse antibody conjugated to HRP, and visualised using ECL development solution.
Protocols
References
This product has been referenced in:
- Ma J et al. Effect of 410 nm photodynamic therapy with hemoporfin on the expression of vascular endothelial growth factor (VEGF) in cultured human vascular endothelial cells. Lasers Med Sci 34:149-155 (2019). Read more (PubMed: 30350123) »
- Fu YC & Xin ZM Inhibited corneal neovascularization in rabbits following corneal alkali burn by double-target interference for VEGF and HIF-1a. Biosci Rep 39:N/A (2019). Read more (PubMed: 30355648) »
